Immunogenicity of the 9-valent human papillomavirus vaccine: Post hoc analysis from five phase 3 studies

Giuliano, Anna; Palefsky, Joel; Goldstone, Stephen; Bornsteind, Jacob; De Coster, Ilse; Guevara, Ana; Mogensen, Ole; Schilling Redlich, Andrea; Van Damme, Pierre; Vandermeulen, Corinne; Ellison, Misoo; Thomas Group; Kaplan, Susan; Lin, Jianxin; Bonawitz, Rachael; Luxembourg, Alain

Publication:
Immunogenicity of the 9-valent human papillomavirus vaccine: Post hoc analysis from five phase 3 studies

Files

Immunogenicity of the 9-valent human papillomavirus vaccine Post hoc analysis from five phase 3 studies.pdf (394.28 KB)

Date

2025

Type:

Article

Collections

Artículos Medicina y Ciencias de la Salud

Descargas totales

0

Vistas totales

1

Métricas

Gestores bibliográficos

Authors

Schilling Redlich, Andrea

Van Damme, Pierre

Vandermeulen, Corinne

item.page.doiurl

https://doi.org/10.1080/21645515.2024.2425146

URI

https://hdl.handle.net/11447/10998

item.page.accessRights

Acceso Abierto

Abstract

Post hoc analyses of 9-valent human papillomavirus (9vHPV) vaccine immunogenicity were conducted in five Phase 3 studies that enrolled males. Month 7 antibody geometric mean titers (GMTs) after three ...

Citation

Giuliano AR, Palefsky JM, Goldstone SE, Bornstein J, De Coster I, Guevara AM, Mogensen O, Schilling A, Van Damme P, Vandermeulen C, Ellison MC; Thomas Group; Kaplan S, Lin J, Bonawitz R, Luxembourg A. Immunogenicity of the 9-valent human papillomavirus vaccine: Post hoc analysis from five phase 3 studies. Hum Vaccin Immunother. 2025 Dec;21(1):2425146. doi: 10.1080/21645515.2024.2425146

Keywords

9-valent HPV vaccine , human papillomavirus , immunogenicity , males

Estadísticas de uso

1 0,8 0,5 0,3 0